Immix Biopharma Files $750 Million Shelf Registration for Stock Offerings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy IMMX?
Source: Benzinga
- New Stock Offering Plan: Immix Biopharma has filed a new S-3 registration statement allowing the company to issue up to $750 million in common stock, preferred stock, and debt securities, providing flexible financing options to support its R&D projects.
- Clear Use of Proceeds: The company plans to use the net proceeds primarily for working capital and general corporate purposes, particularly to advance its CAR-T candidate NXC-201 for AL amyloidosis, highlighting its strategic focus on treating serious diseases.
- Price Volatility Analysis: As of Monday, Immix Biopharma shares fell 4.11% to $4.67, reflecting market concerns over the new stock issuance, while its 52-week price range of $1.34 to $7.73 indicates significant volatility and investment opportunities.
- Technical Outlook: Despite selling pressure, the technical outlook for Immix Biopharma remains cautiously optimistic, with the current stock price above historical lows; if it breaks through the $5.00 resistance level, it could test recent highs near $7.73, attracting more investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMX
Wall Street analysts forecast IMMX stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.290
Low
8.00
Averages
8.00
High
8.00
Current: 9.290
Low
8.00
Averages
8.00
High
8.00
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades, downgrades, and initiations are not detailed in this article, the overall trend suggests fluctuations in analyst confidence, potentially prompting investors to reassess their stock holdings.
- Investor Consideration: For those considering buying VAL stock, analysts' opinions will serve as a crucial reference point, likely impacting their investment decisions and the stock's market performance.
- Market Dynamics Impact: Changes in analyst ratings typically provoke market reactions, necessitating investors to closely monitor these shifts to adjust their investment strategies accordingly.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrade and downgrade details are not provided, such changes typically have a direct impact on the stock prices of the affected companies, necessitating investor vigilance regarding these developments.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to increased buying or selling activity for TFC stock, thereby affecting its trading volume and price fluctuations in the short term.
- Investor Focus: Investors considering purchasing TFC stock should take into account the latest analyst ratings and market sentiment to make more informed investment decisions.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: For those considering buying AKTS stock, analysts' opinions will serve as a crucial reference point, aiding in the assessment of investment risks and potential returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, even though specific rating details are not available.
See More
NXC-201 Receives FDA Breakthrough Therapy Designation
- FDA Designation: NXC-201 has been granted Breakthrough Therapy Designation by the FDA based on positive interim results from the NEXICART-2 clinical trial, marking a significant advancement in treating relapsed/refractory AL Amyloidosis.
- Clinical Trial Progress: The NEXICART-2 trial is expected to enroll 40 patients with a registrational design, aiming to expedite the development of NXC-201, with plans for a Biologics License Application (BLA) submission this year to bring the therapy to market swiftly.
- Market Potential: The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to reach 38,500 by 2026, growing at a rate of 12% per year, providing a robust demand foundation for the market introduction of NXC-201.
- Industry Impact: The AL Amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025, and the successful launch of NXC-201 will help Immix Biopharma secure a leading position in this rapidly expanding market.
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Immix Biopharma Files $750 Million Shelf Registration for Stock Offerings
- New Stock Offering Plan: Immix Biopharma has filed a new S-3 registration statement allowing the company to issue up to $750 million in common stock, preferred stock, and debt securities, providing flexible financing options to support its R&D projects.
- Clear Use of Proceeds: The company plans to use the net proceeds primarily for working capital and general corporate purposes, particularly to advance its CAR-T candidate NXC-201 for AL amyloidosis, highlighting its strategic focus on treating serious diseases.
- Price Volatility Analysis: As of Monday, Immix Biopharma shares fell 4.11% to $4.67, reflecting market concerns over the new stock issuance, while its 52-week price range of $1.34 to $7.73 indicates significant volatility and investment opportunities.
- Technical Outlook: Despite selling pressure, the technical outlook for Immix Biopharma remains cautiously optimistic, with the current stock price above historical lows; if it breaks through the $5.00 resistance level, it could test recent highs near $7.73, attracting more investor interest.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades, downgrades, and initiations are not detailed in this article, the overall trend suggests fluctuations in analyst confidence, potentially prompting investors to reassess their stock holdings.
- Investor Consideration: For those considering buying VAL stock, analysts' opinions will serve as a crucial reference point, likely impacting their investment decisions and the stock's market performance.
- Market Dynamics Impact: Changes in analyst ratings typically provoke market reactions, necessitating investors to closely monitor these shifts to adjust their investment strategies accordingly.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrade and downgrade details are not provided, such changes typically have a direct impact on the stock prices of the affected companies, necessitating investor vigilance regarding these developments.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to increased buying or selling activity for TFC stock, thereby affecting its trading volume and price fluctuations in the short term.
- Investor Focus: Investors considering purchasing TFC stock should take into account the latest analyst ratings and market sentiment to make more informed investment decisions.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: For those considering buying AKTS stock, analysts' opinions will serve as a crucial reference point, aiding in the assessment of investment risks and potential returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, even though specific rating details are not available.
See More
NXC-201 Receives FDA Breakthrough Therapy Designation
- FDA Designation: NXC-201 has been granted Breakthrough Therapy Designation by the FDA based on positive interim results from the NEXICART-2 clinical trial, marking a significant advancement in treating relapsed/refractory AL Amyloidosis.
- Clinical Trial Progress: The NEXICART-2 trial is expected to enroll 40 patients with a registrational design, aiming to expedite the development of NXC-201, with plans for a Biologics License Application (BLA) submission this year to bring the therapy to market swiftly.
- Market Potential: The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to reach 38,500 by 2026, growing at a rate of 12% per year, providing a robust demand foundation for the market introduction of NXC-201.
- Industry Impact: The AL Amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025, and the successful launch of NXC-201 will help Immix Biopharma secure a leading position in this rapidly expanding market.
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Immix Biopharma Files $750 Million Shelf Registration for Stock Offerings
- New Stock Offering Plan: Immix Biopharma has filed a new S-3 registration statement allowing the company to issue up to $750 million in common stock, preferred stock, and debt securities, providing flexible financing options to support its R&D projects.
- Clear Use of Proceeds: The company plans to use the net proceeds primarily for working capital and general corporate purposes, particularly to advance its CAR-T candidate NXC-201 for AL amyloidosis, highlighting its strategic focus on treating serious diseases.
- Price Volatility Analysis: As of Monday, Immix Biopharma shares fell 4.11% to $4.67, reflecting market concerns over the new stock issuance, while its 52-week price range of $1.34 to $7.73 indicates significant volatility and investment opportunities.
- Technical Outlook: Despite selling pressure, the technical outlook for Immix Biopharma remains cautiously optimistic, with the current stock price above historical lows; if it breaks through the $5.00 resistance level, it could test recent highs near $7.73, attracting more investor interest.
See More
